Brighton Jones LLC Sells 118,942 Shares of Pfizer Inc. $PFE

Brighton Jones LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 18.0% in the 2nd quarter, Holdings Channel.com reports. The fund owned 542,777 shares of the biopharmaceutical company’s stock after selling 118,942 shares during the period. Brighton Jones LLC’s holdings in Pfizer were worth $13,157,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. Pacer Advisors Inc. increased its holdings in shares of Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after acquiring an additional 17,957,928 shares in the last quarter. Amundi increased its holdings in shares of Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares in the last quarter. Nuveen LLC bought a new position in shares of Pfizer during the first quarter valued at $389,861,000. Goldman Sachs Group Inc. increased its holdings in shares of Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after acquiring an additional 9,041,990 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on PFE. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Saturday. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.13.

Pfizer Trading Up 0.5%

Shares of NYSE:PFE opened at $24.79 on Friday. The stock has a market capitalization of $140.92 billion, a price-to-earnings ratio of 13.18, a PEG ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock’s 50-day simple moving average is $24.87 and its two-hundred day simple moving average is $24.18. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.